Ortin Global Limited disclosed that its promoters and Persons Acting in Concert (PAC) collectively held 1,00,300 equity shares as of March 31, 2026. The company confirmed that no encumbrance was created on these shares, directly or indirectly, during the financial year ended March 31, 2026, except for those already reported to the stock exchanges.

The disclosure was submitted to BSE Limited and the National Stock Exchange of India Limited in compliance with Regulation 31(4) & (5) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing was signed by S. Murali Krishna Murthy on behalf of the promoters.

Shareholding Details

The table below outlines the shareholding status of the promoters and PAC as of the specified date:

Ortin Global Limited, formerly known as Ortin Laboratories Limited, has a BSE scrip code of 539287. The company’s Audit Committee was also marked as a recipient of the disclosure.

The Committee of Independent Directors of Ortin Global Limited has determined that the offer price of ₹14.65 per equity share is fair and reasonable. The committee reviewed the Public Announcement dated February 10, 2026, the Detailed Public Statement dated February 17, 2026, the Draft Letter of Offer dated February 25, 2026, and the Letter of Offer dated May 26, 2026.

The open offer is made by Mr. Parveen Satija for the acquisition of up to 21,14,162 equity shares of face value of ₹10 each. This represents 26% of the fully paid-up equity share capital and voting capital of the target company. The offer is payable in cash and is made in terms of Regulation 4 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rarever Financial Advisors Private Limited is acting as the Manager to the Offer. The committee members, comprising Mr. Sarang Balbhimrao Patodekar, Mr. Ajay Vishwakarma, and Ms. Mounika Pammi, confirmed they are Independent and Non-Executive Directors with no other relationship with the target company or the acquirer. The committee also confirmed that the target company has not received any complaints from shareholders regarding the open offer process, valuation price, or other matters.

Offer Details